Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: Results of the EPISTENT (Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial) diabetic substudy

Steven P. Marso, A. Michael Lincoff, Stephen G. Ellis, Deepak L. Bhatt, Jean Francois Tanguay, Neal S. Kleiman, Talal Hammoud, Joan E. Booth, Shelly K. Sapp, Eric J. Topol

Research output: Contribution to journalArticle

288 Citations (Scopus)

Abstract

Background - Stenting likely decreases the need for target-vessel revascularization procedures in diabetic patients compared with balloon angioplasty. However, the efficacy of stenting with platelet glycoprotein IIb/IIIa blockade has not yet been assessed in diabetics. Methods and Results - We analyzed the outcomes of 491 diabetic patients within the multicenter Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial (EPISTENT). Diabetic patients were a prospectively defined subset: 173 were randomized to stent-placebo, 162 to stent-abciximab, and 156 to balloon angioplasty- abciximab. The main end point for this analysis was combined 6-month death, myocardial infarction (MI), or target-vessel revascularization (TVR). The composite end point occurred in 25.2% of stent-placebo, 23.4% of balloon- abciximab, and 13.0% of stent-abciximab patients (P=0.005). Abciximab therapy, irrespective of revascularization strategy (stent or balloon angioplasty), resulted in a significant reduction in the 6-month death or MI rate: 12.7% for stent-placebo, 7.8% for balloon angioplasty-abciximab, and 6.2% for the stent-abciximab group (P=0.029). The 6-month TVR rate was 16.6% for stent-placebo, 18.4% for balloon-abciximab, and 8.1% for stent-abciximab (P=0.021). Compared with stent-placebo, stent-abciximab therapy was associated with a significant increase in angiographic net gain (0.88 versus 0.55 mm; P=0.011) and a decrease in the late loss index (0.40 versus 0.60 mm; P=0.061). The 1-year mortality rate for diabetics was 4.1% for stent-placebo and 1.2% for stent-abciximab patients (P=0.11). Conclusions - The combination of stenting and abciximab therapy among diabetics resulted in a significant reduction in 6-month rates of death, MI, and TVR compared with stent-placebo or balloon-abciximab therapy.

Original languageEnglish (US)
Pages (from-to)2477-2484
Number of pages8
JournalCirculation
Volume100
Issue number25
StatePublished - Dec 21 1999

Fingerprint

Stents
Diabetes Mellitus
Blood Platelets
Placebos
Balloon Angioplasty
Myocardial Infarction
abciximab
Integrin beta3
Platelet Glycoprotein GPIIb-IIIa Complex
Mortality
Therapeutics

Keywords

  • Diabetes mellitus
  • Platelet aggregation inhibitors
  • Restenosis
  • Stents

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus : Results of the EPISTENT (Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial) diabetic substudy. / Marso, Steven P.; Lincoff, A. Michael; Ellis, Stephen G.; Bhatt, Deepak L.; Tanguay, Jean Francois; Kleiman, Neal S.; Hammoud, Talal; Booth, Joan E.; Sapp, Shelly K.; Topol, Eric J.

In: Circulation, Vol. 100, No. 25, 21.12.1999, p. 2477-2484.

Research output: Contribution to journalArticle

Marso, SP, Lincoff, AM, Ellis, SG, Bhatt, DL, Tanguay, JF, Kleiman, NS, Hammoud, T, Booth, JE, Sapp, SK & Topol, EJ 1999, 'Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: Results of the EPISTENT (Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial) diabetic substudy', Circulation, vol. 100, no. 25, pp. 2477-2484.
Marso, Steven P. ; Lincoff, A. Michael ; Ellis, Stephen G. ; Bhatt, Deepak L. ; Tanguay, Jean Francois ; Kleiman, Neal S. ; Hammoud, Talal ; Booth, Joan E. ; Sapp, Shelly K. ; Topol, Eric J. / Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus : Results of the EPISTENT (Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial) diabetic substudy. In: Circulation. 1999 ; Vol. 100, No. 25. pp. 2477-2484.
@article{64a0a8bdb988463cbd78ac222b9794a8,
title = "Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: Results of the EPISTENT (Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial) diabetic substudy",
abstract = "Background - Stenting likely decreases the need for target-vessel revascularization procedures in diabetic patients compared with balloon angioplasty. However, the efficacy of stenting with platelet glycoprotein IIb/IIIa blockade has not yet been assessed in diabetics. Methods and Results - We analyzed the outcomes of 491 diabetic patients within the multicenter Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial (EPISTENT). Diabetic patients were a prospectively defined subset: 173 were randomized to stent-placebo, 162 to stent-abciximab, and 156 to balloon angioplasty- abciximab. The main end point for this analysis was combined 6-month death, myocardial infarction (MI), or target-vessel revascularization (TVR). The composite end point occurred in 25.2{\%} of stent-placebo, 23.4{\%} of balloon- abciximab, and 13.0{\%} of stent-abciximab patients (P=0.005). Abciximab therapy, irrespective of revascularization strategy (stent or balloon angioplasty), resulted in a significant reduction in the 6-month death or MI rate: 12.7{\%} for stent-placebo, 7.8{\%} for balloon angioplasty-abciximab, and 6.2{\%} for the stent-abciximab group (P=0.029). The 6-month TVR rate was 16.6{\%} for stent-placebo, 18.4{\%} for balloon-abciximab, and 8.1{\%} for stent-abciximab (P=0.021). Compared with stent-placebo, stent-abciximab therapy was associated with a significant increase in angiographic net gain (0.88 versus 0.55 mm; P=0.011) and a decrease in the late loss index (0.40 versus 0.60 mm; P=0.061). The 1-year mortality rate for diabetics was 4.1{\%} for stent-placebo and 1.2{\%} for stent-abciximab patients (P=0.11). Conclusions - The combination of stenting and abciximab therapy among diabetics resulted in a significant reduction in 6-month rates of death, MI, and TVR compared with stent-placebo or balloon-abciximab therapy.",
keywords = "Diabetes mellitus, Platelet aggregation inhibitors, Restenosis, Stents",
author = "Marso, {Steven P.} and Lincoff, {A. Michael} and Ellis, {Stephen G.} and Bhatt, {Deepak L.} and Tanguay, {Jean Francois} and Kleiman, {Neal S.} and Talal Hammoud and Booth, {Joan E.} and Sapp, {Shelly K.} and Topol, {Eric J.}",
year = "1999",
month = "12",
day = "21",
language = "English (US)",
volume = "100",
pages = "2477--2484",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "25",

}

TY - JOUR

T1 - Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus

T2 - Results of the EPISTENT (Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial) diabetic substudy

AU - Marso, Steven P.

AU - Lincoff, A. Michael

AU - Ellis, Stephen G.

AU - Bhatt, Deepak L.

AU - Tanguay, Jean Francois

AU - Kleiman, Neal S.

AU - Hammoud, Talal

AU - Booth, Joan E.

AU - Sapp, Shelly K.

AU - Topol, Eric J.

PY - 1999/12/21

Y1 - 1999/12/21

N2 - Background - Stenting likely decreases the need for target-vessel revascularization procedures in diabetic patients compared with balloon angioplasty. However, the efficacy of stenting with platelet glycoprotein IIb/IIIa blockade has not yet been assessed in diabetics. Methods and Results - We analyzed the outcomes of 491 diabetic patients within the multicenter Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial (EPISTENT). Diabetic patients were a prospectively defined subset: 173 were randomized to stent-placebo, 162 to stent-abciximab, and 156 to balloon angioplasty- abciximab. The main end point for this analysis was combined 6-month death, myocardial infarction (MI), or target-vessel revascularization (TVR). The composite end point occurred in 25.2% of stent-placebo, 23.4% of balloon- abciximab, and 13.0% of stent-abciximab patients (P=0.005). Abciximab therapy, irrespective of revascularization strategy (stent or balloon angioplasty), resulted in a significant reduction in the 6-month death or MI rate: 12.7% for stent-placebo, 7.8% for balloon angioplasty-abciximab, and 6.2% for the stent-abciximab group (P=0.029). The 6-month TVR rate was 16.6% for stent-placebo, 18.4% for balloon-abciximab, and 8.1% for stent-abciximab (P=0.021). Compared with stent-placebo, stent-abciximab therapy was associated with a significant increase in angiographic net gain (0.88 versus 0.55 mm; P=0.011) and a decrease in the late loss index (0.40 versus 0.60 mm; P=0.061). The 1-year mortality rate for diabetics was 4.1% for stent-placebo and 1.2% for stent-abciximab patients (P=0.11). Conclusions - The combination of stenting and abciximab therapy among diabetics resulted in a significant reduction in 6-month rates of death, MI, and TVR compared with stent-placebo or balloon-abciximab therapy.

AB - Background - Stenting likely decreases the need for target-vessel revascularization procedures in diabetic patients compared with balloon angioplasty. However, the efficacy of stenting with platelet glycoprotein IIb/IIIa blockade has not yet been assessed in diabetics. Methods and Results - We analyzed the outcomes of 491 diabetic patients within the multicenter Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial (EPISTENT). Diabetic patients were a prospectively defined subset: 173 were randomized to stent-placebo, 162 to stent-abciximab, and 156 to balloon angioplasty- abciximab. The main end point for this analysis was combined 6-month death, myocardial infarction (MI), or target-vessel revascularization (TVR). The composite end point occurred in 25.2% of stent-placebo, 23.4% of balloon- abciximab, and 13.0% of stent-abciximab patients (P=0.005). Abciximab therapy, irrespective of revascularization strategy (stent or balloon angioplasty), resulted in a significant reduction in the 6-month death or MI rate: 12.7% for stent-placebo, 7.8% for balloon angioplasty-abciximab, and 6.2% for the stent-abciximab group (P=0.029). The 6-month TVR rate was 16.6% for stent-placebo, 18.4% for balloon-abciximab, and 8.1% for stent-abciximab (P=0.021). Compared with stent-placebo, stent-abciximab therapy was associated with a significant increase in angiographic net gain (0.88 versus 0.55 mm; P=0.011) and a decrease in the late loss index (0.40 versus 0.60 mm; P=0.061). The 1-year mortality rate for diabetics was 4.1% for stent-placebo and 1.2% for stent-abciximab patients (P=0.11). Conclusions - The combination of stenting and abciximab therapy among diabetics resulted in a significant reduction in 6-month rates of death, MI, and TVR compared with stent-placebo or balloon-abciximab therapy.

KW - Diabetes mellitus

KW - Platelet aggregation inhibitors

KW - Restenosis

KW - Stents

UR - http://www.scopus.com/inward/record.url?scp=0033613541&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033613541&partnerID=8YFLogxK

M3 - Article

C2 - 10604884

AN - SCOPUS:0033613541

VL - 100

SP - 2477

EP - 2484

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 25

ER -